NCT03060720

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 271 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations

Detailed description

This research is being done to identify which pancreatic cancer patients should undergo genetic evaluation. A patient's personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines that exist to help doctors use this information to make a decision. The investigators hope that by testing all new pancreatic cancer patients, they can determine which clinical factors predict for genetic mutations in order to create a risk assessment tool. The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. At the Cancer Genetics and Prevention clinic appointment, the provider will review the patient's personal and familial history of cancer and offer genetic testing.

Conditions

• Pancreatic Cancer

Timeline

• Start date: 2017-02-24
• Primary completion: 2019-04-07
• Completion: 2028-02-01
• First posted: 2017-02-23
• Last updated: 2026-03-30

Locations

1 site across 1 country: United States